Accessibility Menu
AIxCrypto logo

AIxCrypto(NASDAQ) QLGN

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-71%
1 Month-24%
N/A
AIxCrypto last closing stock price
MetricPriceDate
Last closeUSD 0.832026-07-27
AIxCrypto stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+19.3%USD 0.692026-07-20
1 month-23.59%USD 1.082026-06-26
3 month-44.24%USD 1.482026-04-28
Year to date-64.74%USD 2.342025-12-31
1 year-70.53%USD 2.802025-07-25
3 year-98.59%USD 58.512023-07-28
5 year-99.91%USD 875.002021-07-28
Since inception-99.97%USD 3,200.002020-05-27

AIxCrypto Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$22.96M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 19, 2026

QLGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AIxCrypto

Qualigen develops medicines for cancer and infectious diseases. Its main focus is on new cancer drugs and a blood-cleansing device. These products aim to help patients with hard-to-treat illnesses and support hospitals in managing complex cases.

What’s in the Medicine Cabinet? (Products and Services)

  • QN-302: Experimental drug for pancreatic cancer; no revenue contribution in 2025.
  • Pan-RAS Program: Early-stage drugs targeting gene mutations in several cancers; no revenue in 2025.
  • QN-247: Gold nanoparticle-based cancer drug candidate; no revenue in 2025.
  • RAS-F: Small molecule drug aiming to block cancer-causing proteins; no revenue in 2025.
  • STARS Blood Cleansing System: Device to remove harmful substances from blood; still in development, no revenue in 2025.
  • Marizyme DuraGraft™ Partnership: Funding for a heart surgery product in exchange for future royalties; no royalties received as of June 2025.

Growth Spurts and Strategic Moves

  • Sold its diagnostic business (Qualigen, Inc, including FastPack) in July 2023 to focus on therapeutics.
  • Entered co-development deal with Marizyme for DuraGraft in April 2024.
  • Secured exclusive licenses from University College London and University of Louisville for key drug candidates.
  • Raised approximately $4.5 million in July 2025 through Series A-3 Preferred Stock.
  • Shifted to a single operating segment focused on cancer drug development in 2024-2025.

What Makes Qualigen Stand Out?

Qualigen’s pipeline targets difficult cancers with new drug approaches. Its partnership model offers potential for future non-dilutive income. The company’s small size allows it to adjust research spending quickly as funding changes.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2023.
  • Operating loss was $2 million in Q2 2025, up 3.3% year-over-year.
  • Cash was $332,000 as of June 30, 2025, down 72% from December 31, 2024.
  • R&D expenses fell 98% year-over-year in Q2 2025.
  • Raised approximately $4.3 million in July 2025 to address liquidity needs.

Bottom Line

Qualigen has shifted from diagnostics to focus on cancer drug development. The company faces funding challenges but continues to pursue new therapies and strategic partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Kevin A. Richardson, II, MBA; Jiawei Wang

Website

www.aixcrypto.ai

Headquarters

Carlsbad, CA 92011, US

QLGN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-94.09%

Return on Capital

-46.99%

Return on Assets

-85.34%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$14.81M

EBITDA

-$14.86M

Operating Cash Flow

-$9.86M

Capital Expenditure

$0.00

Free Cash Flow

-$9.86M

Cash & ST Invst.

$6.20M

Total Debt

$0.00

AIxCrypto Performance Analysis

AIxCrypto annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
AIxCrypto sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
AIxCrypto annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -242.69-20.4%
20232023-12-31USD -126.31-48.0%
20242024-12-31USD -17.28-86.3%
20252025-12-31USD -8.11-53.1%
AIxCrypto sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3045.1%
Q32025-09-30-73.0%
Q42025-12-31-105.8%
Q12026-03-3177.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

4

N/A

Net Income

-$6.08M

-129.7%

EBITDA

-$4.33M

-68.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.20M

+20426.7%

Total Debt

$0.00

-100.0%

Accounts Receivable

$385.43K

-82.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-85.34%

N/A

Return on Invested Capital

-67.72%

N/A

Free Cash Flow

-$4.50M

-182.8%

Operating Cash Flow

-$4.50M

-182.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNGXSoligenix, Inc.
$0.36-2.53%
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%
XBIOXenetic Biosciences, Inc.
$2.50-5.30%
KZIAKazia Therapeutics Ltd ADR
$12.21-0.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About QLGN

What is the current price of AIxCrypto?

AIxCrypto is trading at N/A per share.

What is the 52-week range for AIxCrypto?

Over the past 52 weeks, AIxCrypto has traded between N/A and N/A.

How much debt does AIxCrypto have?

As of the most recent reporting period, AIxCrypto reported total debt of $0.00.

How much cash does AIxCrypto have on hand?

AIxCrypto reported $6.20M in cash and cash equivalents in its most recent financial results.

What is AIxCrypto’s dividend yield?

AIxCrypto does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services